Elio Mazzone

Disclosure information not submitted.

Presentation(s):

• MP27-02: Not All Adverse Pathology Features Are Equal: Identifying Optimal Candidates For Adjuvant Radiotherapy Among Patients With Adverse Pathology at radical Prostatectomy

  Saturday, May 14, 2022
  10:30 AM – 11:45 AM

• PD35-01: Which Patients With cN1 Disease At PET/CT Are Affected By Systemic Disease? Implications For Tailored Treatment Approaches Based On A Large Multi-Institutional Series

  Sunday, May 15, 2022
  7:00 AM – 7:10 AM

• MP51-14: Impact of 68Ga-PSMA PET/CT and Metastasis-Directed Therapy on Clinical Recurrence in Patients with Biochemical Recurrence after Radical Prostatectomy. Results from a Single Center Series

  Sunday, May 15, 2022
  4:30 PM – 5:45 PM

• PD60-02: Can pelvic lymph node dissection be omitted at the time of radical prostatectomy in patients with a negative preoperative 68Ga-PSMA PET/CT? The importance of patient risk stratification according to individual risk of lymph node metastases

  Monday, May 16, 2022
  1:10 PM – 1:20 PM